Stock-Based Compensation: The estimated market value of stock options, warrants and other stock-based compensation given to employees and/or vendors.
Nautilus Biotechnology, Inc. (NAUT) had Stock-Based Compensation of $6.84M for the most recently reported fiscal quarter, ending 2025-12-31.
| Income Statement Financials | |
-- |
|
$-13.78M |
|
-- |
|
-- |
|
$15.42M |
|
$-15.42M |
|
$1.64M |
|
$-13.78M |
|
$-13.78M |
|
$-13.78M |
|
$-13.78M |
|
$-13.78M |
|
$-13.78M |
|
$-15.42M |
|
$-13.97M |
|
126.26M |
|
126.26M |
|
$-0.11 |
|
$-0.11 |
|
| Balance Sheet Financials | |
$105.96M |
|
$3.46M |
|
$85.15M |
|
$191.11M |
|
$7.95M |
|
-- |
|
$26.19M |
|
$34.14M |
|
$156.97M |
|
$156.97M |
|
$156.97M |
|
126.47M |
|
| Cash Flow Statement Financials | |
$-50.70M |
|
$35.22M |
|
$0.21M |
|
$28.65M |
|
$13.39M |
|
$-15.26M |
|
|
Stock-Based Compensation |
$6.84M |
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
13.33 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-51.97M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-8.78% |
|
-8.78% |
|
-7.21% |
|
-8.78% |
|
$1.24 |
|
$-0.41 |
|
$-0.40 |
|